Live Chat ×
Skip to main content

Urologic Pathology in 2017: Emerging Concepts, WHO Classification and AJCC Updated

This item is expired.

Evaluated by: David B. Kaminsky, M.D., FIAC, May 21, 2017
Original release date: November 17, 2017
Access to this course expires on: May 19, 2020, at 11:59 PM Pacific Time
CME/SAMs 13.5

Course Description
The WHO Classification of Tumors of the Urinary System and Male Genital Organs and updates by the American Joint Committee on Cancer are reference points for this extraordinary interactive microscopy course that explicates emerging concepts in the context of these classification/staging systems. The superb faculty are internationally recognized for their expertise in urologic pathology; collaboration with one of the most experienced surgeons in the United States performing robot-assisted radical cystectomy and urinary diversion for patients with bladder cancer provides an open, practical dialogue between clinician and the pathologist course director. This is an intimate experience that will change how you think and perform.

Target Audience
Practicing academic and community pathologists, and pathologists-in-training.

Learning Objectives
Upon completion of this educational activity, learners will be able to:
  • Learn to recognize key diagnostic changes for several entities in urologic pathology
  • Develop diagnostic criteria to recognize recently described entities in urologic pathology
  • Gain an awareness of challenges and changes associated with staging in urologic pathology
  • Learn techniques to enhance cross-disciplinary interaction with radiologists, urologists and oncologists

Continuing Medical Education and Continuing Certification
The United States and Canadian Academy of Pathology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The United States and Canadian Academy of Pathology designates this enduring material for a maximum of 13.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

USCAP is approved by the American Board of Pathology (ABPath) to offer Self-Assessment credits (SAMs) and Lifelong Learning (Part II) credit for the purpose of meeting the ABPath requirements for Continuing Certification (CC). Registrants must take and pass the post-test in order to claim SAMs credit. Physicians can earn a maximum of 13.5 SAM/Part II credit hours.

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to USCAP and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. USCAP has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The following faculty reported no relevant financial relationships: Donna E. Hansel, M.D., Ph.D., John Cheville, M.D., Michelle S. Hirsch, M.D., Ph.D., Peter A. Humphrey, M.D., Ph.D., Karim A. Kader, M.D., Ph.D., John R. Srigley, M.D., FRCPC, FRCPath, FRCPA [Hon.]

The following IM Coordinator reported no relevant financial relationships: Adeboye O. Osunkoya, MD

USCAP staff associated with the development of content for this activity reported no relevant financial relationships.

Purchase the entire course and save - USCAP Members and Trainee Members, sign-in to save an additional amount!

Not a Member?  Click Here